A Long Road Ahead for This Embattled Blood Thinner

The enormous rough diamond that Merck picked up in the Schering-Plough merger has been cut smaller and smaller during costly late stage development. Soon, investors will know if it has a chance of recouping its costs.

Jan 6, 2014 at 4:48PM

The enormous rough diamond, called vorapaxar, that Merck (NYSE:MRK) picked up in the Schering-Plough merger has been cut smaller and smaller during costly late-stage development. The first big setback was a pricey phase 3 trial that measured the prevention of clinical events in patients with acute coronary syndrome. In November 2011, the company announced that the drug did not meet its original endpoint. This failure basically buried the drug's chances of being a primary blood thinner for anyone at risk of heart attack.

Less than half a year later, Merck presented data from a phase 3 trial that measured vorapaxar's ability to reduce risk of cardiovascular events as a secondary prevention in patients with a previous heart attack or stroke. This trial did reach its endpoint, but there was a significant increase in intracranial hemorrhage among patients that had previously suffered a stroke. Again, the potential patient pool for vorapaxar became smaller.

A must win
The FDA intends to kick off the year with a series of three cardiovascular and renal drugs advisory committee meetings. On Jan. 15, they'll be discussing a New Drug Application, or NDA, from Merck for vorapaxar. The FDA accepted the NDA for standard review in July. Merck is seeking its approval for the secondary prevention of cardiovascular events in patients with a history of heart attack, but no history of stroke or ischemic attack.

The advisory committee meeting on the 15th could be the final nail in vorapaxar's very expensive coffin. A recent study conducted by the McKinsey Center for Government shows the regulator is strongly aligned with the opinions of its independent advisory committees. During NDA and BLA focused meetings that include voting, the FDA approved nearly 88% of drugs endorsed by the committee. Over the period from 2001-2010, only two of 14 drugs not endorsed by an advisory committee later won approval.

Some success
So far it doesn't look like much of a competitor. Although vorapaxar employs a different method of preventing clots than Plavix, it is hardly the wonder drug that Merck hoped it would be. The TRA-2P trial enrolled thousands of patients that had previously suffered heart attack or stroke. About 11.2% of those taking vorapaxar suffered cardiovascular death, myocardial infarction, stroke, or urgent coronary revascularization, versus 12.4% in the placebo group. The decrease of 1.2% might be statistically significant, but hardly exciting when combined with the documented risk of cranial hemorrhaging.

Questionable now equals excluded
Vorapaxar isn't the only blood thinner likely to experience pressure from cheap generic clopidogrel. Pharmacy benefit manager Express Scripts (NASDAQ:ESRX) is hammering away at higher cost drugs with incremental benefits. During the three months ended Sept. 30, the company raised its generic fill rate to 80.7% from 78% during the same period of the previous year. For 2014, the company updated its National Preferred Formulary to exclude 48 high-cost medications of questionable benefit with covered preferred alternatives. For Express Scripts, "preferred" usually means "inexpensive" generics.

The competition
The FDA approved generic versions of the Bristol-Myers Squibb blockbuster clopidogrel (Plavix) in May 2012. If vorapaxar does woo the committee, then later win approval, it will be competing for recent heart attack patients with an inexpensive option that physicians have had plenty of time to become comfortable with.

Luckily for Eli Lilly (NYSE:LLY), its blood thinner Effient is on the Express Scripts formulary. U.S. sales of the clot preventer reached $339 million in 2012. During the first nine months of 2013, overall sales of Effient rose 12% on year.

Effient is marketed specifically to patients that have undergone an artery opening procedure, but not necessarily sufferers of a previous heart attack. If approved, vorapaxar is likely to compete with this platelet inhibitor for some patients. Like vorapaxar, Effient also has a history of bleeding complications.

Also escaping the exclusion list is Brilinta from AstraZeneca (NYSE:AZN). This blood thinner is approved for the primary prevention of cardiovascular events in patients with acute coronary syndrome, not necessarily those with a history of heart attack. If approved, vorapaxar will likely compete with this platelet inhibitor, along with generic versions of Plavix.

AstraZeneca and Brilinta could take a serious turn for the worse in the near future. Both, the US Department of Justice and EU regulators are investigating the phase 3 trial, named PLATO, that pitted Brilinta against Plavix. Data from PLATO was used to show superiority over Plavix, and in turn to demand a much higher price. Drugmaker investigations are rarely worth getting excited about, but this one comes on the heels of a journal article published in the International Journal of Cardiology criticizing the reliability of trial data.

Take the shot
Pleasing the advisory committee on Jan. 15 would almost certainly cement a chance for vorapaxar to recoup some of the resources spent acquiring and developing the compound. The drug's different mechanism of action might be enough for payers and physicians to try it alongside existing treatments. Also, if the investigation of the PLATO trial turns out badly for AstraZeneca, it could play right into Merck's hand.

It's a long shot, but with both trials already paid for, it's certainly one worth taking. Let's just hope Merck doesn't initiate another vorapaxar trial if it doesn't win this time around.

The Fool's top stock for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Cory Renauer has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information